AbbVie
Trade AbbVie 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About ABBV
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions.
ABBV Key Statistics
Stock Snapshot
AbbVie(ABBV) stock is priced at $208.27, giving the company a market capitalization of 369.19B. It carries a P/E multiple of 88.45 and pays a dividend yield of 3.2%.
As of 2026-04-03, AbbVie(ABBV) stock has fluctuated between $207.72 and $214.99. The current price stands at $208.27, placing the stock +0.3% above today's low and -3.1% off the high.
The AbbVie(ABBV)'s current trading volume is 5.15M, compared to an average daily volume of 8.53M.
During the past year, AbbVie(ABBV) stock moved between $164.39 at its lowest and $244.81 at its peak.
During the past year, AbbVie(ABBV) stock moved between $164.39 at its lowest and $244.81 at its peak.
ABBV News
In late March 2026, AbbVie detailed extensive new clinical and real-world dermatology data for Skyrizi and Rinvoq at the American Academy of Dermatology meeting...
If you are wondering whether AbbVie at around US$214.98 is a fair deal or a stretch at current levels, this article walks through what the numbers are actually...
Analyst Evan Seigerman of BMO Capital maintained a Buy rating on AbbVie, retaining the price target of $258.00. Unlock hedge fund-level data and powerful inves...
Analyst ratings
67%
of 33 ratingsMore ABBV News
AbbVie’s Allergan Aesthetics unit is running its fourth annual CoolMonth promotion in April 2026, offering new patients discounts on CoolSculpting treatments....
Key Points The Schwab U.S. Dividend Equity ETF recently completed its annual reconstitution. It added two new healthcare stocks to its top 10. Healthcare is...
Advertisement AbbVie’s dermatology data and why it matters for the stock AbbVie (ABBV) just put a spotlight on its dermatology franchise at the 2026 American...
Abbvie (ABBV) announced an update on their ongoing clinical study. AbbVie is running a global observational study called “Treat-to-Target and Disease Modificat...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.